CU24508B1 - Composición farmacéutica que comprende péptido tipo apl - Google Patents
Composición farmacéutica que comprende péptido tipo aplInfo
- Publication number
- CU24508B1 CU24508B1 CU2017000176A CU20170176A CU24508B1 CU 24508 B1 CU24508 B1 CU 24508B1 CU 2017000176 A CU2017000176 A CU 2017000176A CU 20170176 A CU20170176 A CU 20170176A CU 24508 B1 CU24508 B1 CU 24508B1
- Authority
- CU
- Cuba
- Prior art keywords
- pharmaceutical composition
- composition including
- type peptide
- inflammatory diseases
- apl type
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 2
- 208000003456 Juvenile Arthritis Diseases 0.000 abstract 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 230000006329 citrullination Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 239000007974 sodium acetate buffer Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
<p>La invención provee una composición farmacéutica que comprende el péptido tipo APL identificado como SEQ ID No. 1, el tampón acetato de sodio a pH 3,9- 4,7; y al menos un azúcar estabilizante seleccionado entre Ia sacarosa y Ia trehalosa. Dicha composición farmacéutica es útil para Ia fabricación de un medicamento para tratar las enfermedades inflamatorias relacionadas con un aumento de los neutrófilos o de Ia citrulinación de proteínas. Entre estas enfermedades inflamatorias se encuentran Ia artritis reumatoide (AR), Ia artritis idiopática juvenil (AIJ), Ia espondilitis anquilosante (EA), Ia enfermedad de Alzheimer, y Ia fibrosis hepática o pulmonar.<br /> </p>
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000176A CU24508B1 (es) | 2017-12-29 | 2017-12-29 | Composición farmacéutica que comprende péptido tipo apl |
| BR112020013033-8A BR112020013033A2 (pt) | 2017-12-29 | 2018-12-21 | composição farmacêutica, uso da composição farmacêutica, e, método para tratamento de uma doença inflamatória. |
| EP18845399.7A EP3733196B1 (en) | 2017-12-29 | 2018-12-21 | Pharmaceutical composition comprising an altered peptide ligand (apl) type peptide |
| CA3086280A CA3086280C (en) | 2017-12-29 | 2018-12-21 | Pharmaceutical composition comprising an apl peptide |
| RU2020124953A RU2778402C2 (ru) | 2017-12-29 | 2018-12-21 | Фармацевтическая композиция, содержащая пептид apl-типа |
| JP2020536159A JP7209000B2 (ja) | 2017-12-29 | 2018-12-21 | Ａｐｌ型ペプチドを含む医薬組成物 |
| CN201880090158.9A CN111741763B (zh) | 2017-12-29 | 2018-12-21 | 包含apl型肽的药用组合物 |
| KR1020207021876A KR102676701B1 (ko) | 2017-12-29 | 2018-12-21 | Apl 형 펩타이드를 포함하는 약제학적 조성물 |
| ES18845399T ES2960415T3 (es) | 2017-12-29 | 2018-12-21 | Composición farmacéutica que comprende un péptido de tipo ligando peptídico alterado (LPA) |
| US16/958,586 US20200353040A1 (en) | 2017-12-29 | 2018-12-21 | Pharmaceutical Composition Comprising an APL Type Peptide |
| ARP180103792A AR114389A1 (es) | 2017-12-29 | 2018-12-21 | Composición farmacéutica que comprende péptido tipo apl |
| MX2020006840A MX2020006840A (es) | 2017-12-29 | 2018-12-21 | Composicion farmaceutica que comprende un peptido tipo apl. |
| PCT/CU2018/050007 WO2019129315A1 (es) | 2017-12-29 | 2018-12-21 | Composición farmaceutica que comprende un peptido tipo apl |
| ZA2020/04658A ZA202004658B (en) | 2017-12-29 | 2020-07-28 | Pharmaceutical composition comprising an apl type peptide |
| US18/394,284 US20240316147A1 (en) | 2017-12-29 | 2023-12-22 | Pharmaceutical composition comprising an apl type peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000176A CU24508B1 (es) | 2017-12-29 | 2017-12-29 | Composición farmacéutica que comprende péptido tipo apl |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20170176A7 CU20170176A7 (es) | 2019-08-06 |
| CU24508B1 true CU24508B1 (es) | 2021-04-07 |
Family
ID=65351834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2017000176A CU24508B1 (es) | 2017-12-29 | 2017-12-29 | Composición farmacéutica que comprende péptido tipo apl |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200353040A1 (es) |
| EP (1) | EP3733196B1 (es) |
| JP (1) | JP7209000B2 (es) |
| KR (1) | KR102676701B1 (es) |
| CN (1) | CN111741763B (es) |
| AR (1) | AR114389A1 (es) |
| BR (1) | BR112020013033A2 (es) |
| CU (1) | CU24508B1 (es) |
| ES (1) | ES2960415T3 (es) |
| MX (1) | MX2020006840A (es) |
| WO (1) | WO2019129315A1 (es) |
| ZA (1) | ZA202004658B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021030257A1 (en) * | 2019-08-14 | 2021-02-18 | The Regents Of The University Of California | Car-t cells specific for modified proteins in extracellular spaces |
| CU24626B1 (es) | 2019-12-26 | 2022-11-07 | Centro Nac De Biopreparados | Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana |
| CU20200026A7 (es) * | 2020-04-13 | 2021-11-04 | Ct Ingenieria Genetica Biotecnologia | Péptido para el tratamiento del síndrome de la tormenta de citocinas |
| CN111870697B (zh) * | 2020-09-18 | 2022-09-09 | 山东鲁抗医药股份有限公司 | 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物 |
| JP2025525629A (ja) * | 2022-07-22 | 2025-08-05 | セントロ デ インジエニエリア ジエネテイカ イ バイオテクノロジア | アポリポタンパク質ａｉまたはトランスサイレチンの関与に関連する疾患の処置のためのペプチド |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23504A1 (es) | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| JP2009534390A (ja) | 2006-04-21 | 2009-09-24 | アムジェン インコーポレイテッド | 生物医薬品製剤のための緩衝剤 |
| US9345753B2 (en) | 2008-01-16 | 2016-05-24 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Vaccine for alzheimer's disease |
| EA023302B9 (ru) * | 2008-06-04 | 2016-10-31 | Модиквест Б.В. | Способ предотвращения или лечения артрита и применение антитела, специфически реактивного к цитруллинированному эпитопу в этом способе |
| CU23701A1 (es) * | 2008-12-29 | 2011-09-21 | Ct Ingenieria Genetica Biotech | Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i |
-
2017
- 2017-12-29 CU CU2017000176A patent/CU24508B1/es unknown
-
2018
- 2018-12-21 EP EP18845399.7A patent/EP3733196B1/en active Active
- 2018-12-21 JP JP2020536159A patent/JP7209000B2/ja active Active
- 2018-12-21 US US16/958,586 patent/US20200353040A1/en not_active Abandoned
- 2018-12-21 AR ARP180103792A patent/AR114389A1/es unknown
- 2018-12-21 KR KR1020207021876A patent/KR102676701B1/ko active Active
- 2018-12-21 BR BR112020013033-8A patent/BR112020013033A2/pt not_active Application Discontinuation
- 2018-12-21 WO PCT/CU2018/050007 patent/WO2019129315A1/es not_active Ceased
- 2018-12-21 MX MX2020006840A patent/MX2020006840A/es unknown
- 2018-12-21 ES ES18845399T patent/ES2960415T3/es active Active
- 2018-12-21 CN CN201880090158.9A patent/CN111741763B/zh active Active
-
2020
- 2020-07-28 ZA ZA2020/04658A patent/ZA202004658B/en unknown
-
2023
- 2023-12-22 US US18/394,284 patent/US20240316147A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR114389A1 (es) | 2020-09-02 |
| JP2021508711A (ja) | 2021-03-11 |
| RU2020124953A (ru) | 2022-01-31 |
| JP7209000B2 (ja) | 2023-01-19 |
| CN111741763B (zh) | 2024-06-14 |
| CN111741763A (zh) | 2020-10-02 |
| BR112020013033A2 (pt) | 2020-12-01 |
| ES2960415T3 (es) | 2024-03-04 |
| US20240316147A1 (en) | 2024-09-26 |
| RU2020124953A3 (es) | 2022-01-31 |
| WO2019129315A1 (es) | 2019-07-04 |
| KR102676701B1 (ko) | 2024-06-20 |
| EP3733196A1 (en) | 2020-11-04 |
| EP3733196B1 (en) | 2023-08-30 |
| MX2020006840A (es) | 2020-09-03 |
| ZA202004658B (en) | 2022-01-26 |
| CA3086280A1 (en) | 2019-07-04 |
| KR20200105869A (ko) | 2020-09-09 |
| US20200353040A1 (en) | 2020-11-12 |
| CU20170176A7 (es) | 2019-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24508B1 (es) | Composición farmacéutica que comprende péptido tipo apl | |
| MX2024002398A (es) | Proteinas de fusion gdf15 y usos de estas. | |
| EA202192588A1 (ru) | Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| CY1124493T1 (el) | Υγρη φαρμακευτικη συνθεση | |
| CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
| RU2017101667A (ru) | Фармацевтические композиции | |
| MX381665B (es) | Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos. | |
| EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
| CY1114185T1 (el) | Υποδοριο σκευασμα αντισωματος αντι-her2 | |
| BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
| NO20090780L (no) | Human Glp-1 mimetistoff, sammensetninger, fremgangsmater og anvendelser | |
| MX2020006822A (es) | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. | |
| ES3053508T2 (en) | Liquid pharmaceutical composition of adalimumab | |
| PE20210918A1 (es) | Composiciones y metodos para el tratamiento de la distrofia macular | |
| MX2021003904A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. | |
| JP2017503505A5 (es) | ||
| BR112019007796A2 (pt) | construção de vacina e seus usos contra infecções causadas por staphylococcus | |
| JP2015525237A5 (es) | ||
| AR086672A1 (es) | Formulaciones de furina recombinante | |
| CU24545B1 (es) | Péptido antagonista de la actividad de la interleucina-15 | |
| PE20242117A1 (es) | Acido nucleico optimizado por codones que codifica la proteina del factor de coagulacion ix, y su uso | |
| MX2022006085A (es) | Formulaciones parenterales estables de duloxetina. | |
| EA202191065A1 (ru) | Конструкции нуклеиновых кислот и способы их применения |